A cross-border life science investment firm that focuses on the pharmaceutical, medical device, and diagnostics sectors. Currently, the firm has close to $1B AUM. In addition to investing in Chinese and American companies, the firmis actively involved in supporting our portfolio companies through cross-border partnerships. The firm generally makes investments ranging from $5-$30 MM USD.

For pharmaceuticals, the firm looks at assets ranging from Ph I to marketed with a preference towards post-Phase IIb products. For medical device products, the firm looks at a wide variety of products with a preference for technologies that are soon to be market ready. Sector interests include but are not limited to cardiovascular, surgical, ENT, orthopedics, wound care, robotics, and others. For diagnostics, the firm invests in a broad range of technology including POCT, IVD, and molecular diagnostics but also targets non-conventional and invasive diagnostics (such as IVUS/OCT, breath based, GI, etc…). The firm is also interested in revenue generating companies working in the animal health space.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a healthcare distribution and information technology solutions company is a stage-agnostic investor, and makes investments from Series A to growth stage. Investments are therefore varied in size relative to the type of investment; initial allocations are most often from $3-7 million with the possibility of follow-on investments up to $15 million. The firm is open to opportunities worldwide but has previously focused on investing in the USA, Canada and Europe.

The firm focuses on four key areas of innovation in healthcare; alternative care delivery models, consumer health, pharma value chain, and data value chain. The firm invests in technologies at all stages.

The firm has no set requirements for IRR or other metrics, but instead focuses on how a company’s technology fits with the four focus areas of the firm’s investment space, and how the firm can potentially add value to the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC firm based in CA invests in companies in Consumer & FinTech, Blockchain, Enterprise & Big Data as well as Life Science & Digital Health. For companies in the life sciences, the firm generally invests in Series A-C rounds, committing between $1-10M in capital. The firm is willing to invest in both the US and China, and will consider companies in pre-clinical and clinical development.

Within the life sciences, the firm is willing to invest in therapeutics, diagnostics, medtech, digital health and R&D services. For therapeutics, the firm will consider traditional therapeutics that are first-in-class, either a novel target or novel therapeutic, but is agnostic to indication. For diagnostics, medtech, digital health and R&D services, the firm focuses on AI-based technologies. Previous investments include AI-based drug discovery platforms, pathology screening, diagnostic services and care management platforms.

The firm looks for companies with a strong management team, large market opportunity and a disruptive technology. When investing, the firm is willing lead or co-invest, and will occasionally take a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm founded and based in California, USA invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $250K to $1M (usually in equity or convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Seed and Series A financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.

Historically, the firm has invested in technology and life sciences, with notable biotech investments in Amgen and Biogen. Today, the firm has a focus on the digital health and informatics space, but also invests in novel therapeutics. The firm is agnostic in terms of subsectors and indications, including orphan indications. The firm will only consider technologies with proof of concept and strong scientific rationale. Historically, the firm has invested in therapeutics that address oncology, infectious diseases, cardiovascular, and metabolic disorders; drug delivery; orthopedic devices; genomics.

The firm takes a board seat in some cases, and prefers to syndicate on opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm is focused on technologies that enhance the human experience and contribute to their well-being. For initial investment, the firm will invest $100-500K and will reserve some funds for follow-on investment. The firm invests mainly in Seed to Series A rounds and often acts as the first institutional investor. Currently, the firm is focused on investing in companies based in the USA, and aims to make 8-10 investments in bio/healthcare technologies.

The firm is interested in companies dedicated to genetics, microbiome, personal pharmaceuticals/diagnostics, VR/AR, consumer-facing medtech or digital health technologies, etc. The firm does not invest in traditional biopharmaceuticals or medical devices, but open to those that require 510k approval.

The firm is open to working with all types of management teams and has no specific management requirements. They could lead the round at seed stage but typically syndicate with other investors for Series A. The firm will take an active role in supporting their companies with needed guidance and resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC fund is focused on the earliest stage companies looking to expand to the Chinese market. The firm will invest between $50-250K in companies that are preclinical/in development and looks to be a strategic partner, either by helping the company enter the Chinese market, or find a licensing opportunity with one of the firm’s strategic partners in China. The firm is looking for therapeutic, medical device or diagnostics companies, but will generally not consider digital health companies due to the difficulty in adapting them to the Chinese market. The firm is currently looking to make about 4 investments a year, about 1 per quarter.

The firm is currently focused primarily on medical devices, but will consider therapeutics and diagnostics as well. For medical devices, the firm prefers 510k pathway. The firm is generally agnostic to subsector and indication, but is seeking technologies that are relevant to the Chinese market.

While it is not required, the firm prefers to take a board seat after investing, since they are looking to be active strategic partners in each company in which the firm invests.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in the USA invests in life science companies at the Seed or Series A stage. The firm will consider opportunities throughout the US and Canada but has a focus on the US East Coast and Midwest. The firm’s investment size ranges from $100,000-$250,000 for seed rounds up to as much as $5 million for Series A opportunities, and the firm may also participate in follow-on investments for their portfolio companies.

The firm is interested in medtech, diagnostics, digital health, biotech, and other applications in life sciences such as technologies that improve lab processes. The firm also has interest in therapeutic platform opportunities, but less in companies developing single drug assets. The firm is open to investing in early stage technologies, including devices that have yet to enter human clinical trials.

The firm will consider investing in companies that have obtained data from a prototype, pilot study, or early stage clinical trial. The firm will also consider investing in management teams that have a successful track record with similar types of technologies and targets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.